drugset / Trial / NCT05429398
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
It is a single-arm, open-label, multicenter, phase I trial,aiming at exploring the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,observing the preliminary efficacy.
Timeline
- Start
- 2022-06-30
- Primary completion
- 2023-08-31
- Completion
- 2024-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linperlisib | Small molecule | 40 mg | Oral |
| Subject | Linperlisib | Small molecule | 60 mg | Oral |
| Subject | Linperlisib | Small molecule | 80 mg | Oral |
| Background | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |